Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor ...

Not unlike Regeneron’s acquisition of 23andMe, Predictive Oncology’s AI-driven breakthroughs reflect ... early drug discovery and enable drug development for the benefit of cancer patients ...

Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Sanofi (ENXTPA:SAN) recently entered into a multi-year partnership with Viz.ai and Regeneron to develop an AI-powered solution for COPD management, reflecting its focus on innovation. Over the last ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment ...

The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this ...

A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics ...

We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...